login
login
Image header Agence Europe
Europe Daily Bulletin No. 12610
Contents Publication in full By article 19 / 39
ECONOMY - FINANCE - BUSINESS / Competition

Teva and Cephalon fined €60.5 million for delaying market entry of a cheaper generic drug

On Thursday, 26 November, the European Commission decided to impose €60.5 million in fines on the pharmaceutical companies Teva (Israel) and Cephalon (United States) because these companies agreed to delay the market entry of a cheaper generic version of Cephalon’s medication for sleep disorders modafinil after the expiry of Cephalon’s main patents.

The agreement—concluded well before Cephalon became a subsidiary of Teva—“violated EU antitrust rules and caused substantial...

Contents

INSTITUTIONAL
EUROPEAN PARLIAMENT PLENARY
ECONOMY - FINANCE - BUSINESS
EXTERNAL ACTION
SECURITY - DEFENCE
SECTORAL POLICIES
NEWS BRIEFS
CORRIGENDUM